Organogenesis Holdings Inc ORGO.OQ ORGO.O is expected to show a fall in quarterly revenue when it reports results on May 8 for the period ending March 31 2025
The Canton Massachusetts-based company is expected to report a 17.5% decrease in revenue to $90.767 million from $109.98 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.The company's guidance on February 27 2025, for the period ended March 31, was for revenue between $85.00 million and $95.00 million.
LSEG's mean analyst estimate for Organogenesis Holdings Inc is for a loss of 6 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Organogenesis Holdings Inc is $6.00, above its last closing price of $5.20.
The company's guidance on February 27 2025 for the period ended March 31 was for gross profit margin between USD76% and USD78%.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
0.00
-0.01
0.06
Beat
580
Sep. 30 2024
-0.02
-0.01
0.09
Beat
700
Jun. 30 2024
0.00
0.00
0.04
Beat
Mar. 31 2024
-0.03
-0.03
-0.02
Beat
25
Dec. 31 2023
0.01
0.01
0.00
Missed
-100
Sep. 30 2023
0.00
0.01
0.02
Beat
300
Jun. 30 2023
0.02
0.03
0.04
Beat
60
Mar. 31 2023
-0.02
-0.02
-0.02
Met
0
This summary was machine generated May 6 at 23:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)